Lenalidomide Ratiopharm

Lenalidomide, the active ingredient in Lenalidomide Ratiopharm, is an immunomodulatory agent presented as a tablet for oral use. It treats certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients, and is classified as an antineoplastic (hematologic oncology) drug available only by prescription.

GNH USA supplies Lenalidomide Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic oncology to target malignant plasma cells and dysplastic marrow clones. - Multiple Myeloma: reduces disease progression and improves survival in adult patients. - Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic response. - Mantle Cell Lymphoma: contributes to disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin redness or itching. - Nausea: upset stomach and possible vomiting.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers during treatment.

Before prescribing Lenalidomide, clinicians should consider several safety precautions. - Pregnancy risk: contraindicated in pregnancy (Category X); ensure effective contraception. - Thrombosis risk: assess for history of clotting disorders and consider prophylaxis. - Hematologic monitoring: perform regular blood counts to detect neutropenia or anemia. - Renal impairment: adjust use in patients with severe kidney dysfunction. - Drug interactions: review concomitant medications for major interaction potential. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lenalidomide can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Immunosuppressants (e.g., cyclosporine): heightened toxicity risk.

Moderate Interactions (Monitor Closely): - P-glycoprotein inhibitors (e.g., quinidine): may increase plasma levels. - NSAIDs: potential for additive renal toxicity. - Live attenuated vaccines: reduced vaccine efficacy, consider timing.